13 patients were dead in Japan with side effects of Iressa

Published: 2002-10-22 06:57:00

Updated: 2002-10-22 06:57:00

AstraZeneca's Iressa, which was first approved on July 16, 2002, by the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of advanced non-small-cell lung cancer, was reported to cause severe side effects, such as, interstitial pneumonia and 13 patients in Japan were dead.
...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK